Clinical Trial Update: Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults [Phase 2]

View source ↗

Summary

A Phase 2 follow-up study by GlaxoSmithKline Biologicals evaluating the HPV vaccine to prevent cervical HPV infection in young adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 2 | Status: COMPLETED